Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Fineline Cube Jul 10, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Deals

Menarini and OrigiMed Partner on Pan-Cancer Single-Cell Diagnostic Platform

Fineline Cube Sep 23, 2022

Italy’s Menarini Group has formed a strategic partnership with China-based precision medicine firm OrigiMed to...

Company Deals

Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions

Fineline Cube Sep 23, 2022

Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is...

Company Deals

InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade

Fineline Cube Sep 23, 2022

China-based InnoCare Pharma (HKG: 9969) has completed an initial public offering (IPO) of 265 million...

Company Drug

Humanwell’s Generic Clobazam Approved for Lennox-Gastaut Syndrome in China

Fineline Cube Sep 23, 2022

China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version of Sanofi’s clobazam (trade name: Frisium) has...

Company Deals

AIM Vaccine Plans IPO to Fund Vaccine R&D and Pipeline Expansion

Fineline Cube Sep 23, 2022

China-based AIM Vaccine Co., Ltd plans to make an initial public offering (IPO) of 9.71...

Company Drug

AstraZeneca and Merck’s Lynparza Receives New Approval in China

Fineline Cube Sep 22, 2022

UK-based AstraZeneca (NASDAQ: AZN) and US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) have announced...

Company Deals

Shandong Luoxin Partners with Shanghai Pharma for Strategic Services

Fineline Cube Sep 22, 2022

China-based Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793) has announced a partnership with...

Policy / Regulatory

NHSA Releases Guide on Volume-Based Procurement Drug Equivalents

Fineline Cube Sep 22, 2022

The National Healthcare Security Administration (NHSA) has reportedly released a reference guide for industry players,...

Company Drug

Zelgen Biopharmaceuticals Gains NMPA Approval for Jacktinib Clinical Trial in SLE

Fineline Cube Sep 22, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Deals Policy / Regulatory

F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review

Fineline Cube Sep 22, 2022

UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...

Company Deals Digital

Shenzhen NeuroPlus Secures Seed Funding for Neuromodulation and Bioelectronic Medicine

Fineline Cube Sep 22, 2022

Shenzhen NeuroPlus has reportedly raised “tens of millions” of renminbi in a seed financing round...

Company

Merck KGaA Opens Viral Clearance Lab in Shanghai’s Biologics Testing Center

Fineline Cube Sep 22, 2022

German pharmaceutical giant Merck KGaA has opened a viral clearance (VC) laboratory as part of...

Company Deals

METiS Therapeutics In-Licenses Voronoi’s Pan-RAF Inhibitor Program

Fineline Cube Sep 22, 2022

Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi...

Policy / Regulatory

Heilongjiang Launches ‘Longjiang Huiminbao’ Supplementary Health Insurance Scheme

Fineline Cube Sep 22, 2022

Heilongjiang province has launched its first provincial-level supplementary commercial health insurance scheme, branded “Longjiang Huiminbao.”...

Company Deals

Immuno Cure BioTech Acquires Majority Stake in Shanghai Teresa Healthcare

Fineline Cube Sep 21, 2022

Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in...

Company Drug

Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA

Fineline Cube Sep 21, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...

Company Deals

Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2

Fineline Cube Sep 21, 2022

Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese...

Company Drug

Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...

Company Deals

Koutech Robotics Secures Series A Funding for Surgical Innovation

Fineline Cube Sep 21, 2022

China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has...

Company Drug

CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit

Fineline Cube Sep 21, 2022

China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...

Posts pagination

1 … 649 650 651 … 693

Recent updates

  • PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates
  • Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia
  • Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
  • Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.